^
    5d
    E711-19 placement and orientation dictate CD8+ T cell response in structurally defined spherical nucleic acid vaccines. (PubMed, Sci Adv)
    Herein, three SNAs were designed with HLA-A2-restricted HPV16 E711-19 peptide and CpG adjuvant, nearly identical in composition but differing in antigen presentation...Transcriptomic profiling revealed up-regulation of activation genes and suppression of exhaustion markers. In patient-derived HPV+ head and neck cancer spheroids, N-HSNA enhanced cytotoxicity ~2.5-fold, establishing antigen placement and orientation as key parameters for translational cancer immunotherapy.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
    |
    DPX-E7
    6d
    A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer (clinicaltrials.gov)
    P1/2, N=20, Completed, Mayo Clinic | Active, not recruiting --> Completed | Trial completion date: Oct 2026 --> Apr 2025 | Trial primary completion date: Oct 2026 --> Apr 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • Versamune HPV
    11d
    TG4001.12: Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers (clinicaltrials.gov)
    P1/2, N=143, Active, not recruiting, Transgene | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Bavencio (avelumab) • tipapkinogene sovacivec (TG4001)
    27d
    A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC) (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=10 --> 7
    Enrollment closed • Enrollment change
    |
    NavDx®
    |
    eseba-vec (HB-200) • HB-201
    3ms
    TSCAN-002: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=840, Active, not recruiting, TScan Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Pan tumor
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702
    4ms
    VERSATILE-003: Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P3, N=351, Active, not recruiting, PDS Biotechnology Corp. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Versamune HPV
    4ms
    QUILT-3.100: IBRX-042 In Participants With HPV-Associated Tumors (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, ImmunityBio, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2025 --> Sep 2027
    Enrollment closed • Trial primary completion date
    5ms
    VERSATILE-002: Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC (clinicaltrials.gov)
    P2, N=95, Completed, PDS Biotechnology Corp. | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • Versamune HPV
    5ms
    H-200-001: A Phase 1/2 Study in Patients With HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Other Cancers (clinicaltrials.gov)
    P1/2, N=198, Completed, Hookipa Biotech GmbH | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Jan 2025 | Trial primary completion date: Jun 2025 --> Jan 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • eseba-vec (HB-200) • HB-201
    7ms
    Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV (clinicaltrials.gov)
    P2, N=27, Not yet recruiting, Weill Medical College of Cornell University
    New P2 trial
    |
    Versamune HPV
    7ms
    Discovery of HPV T Cell Epitopes and Development of Multi-epitope Vaccines (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Anhui Provincial Hospital
    New trial
    |
    HPV-T
    7ms
    VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions (clinicaltrials.gov)
    P2, N=35, Completed, AIDS Malignancy Consortium | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Jun 2025 | Trial primary completion date: Jun 2025 --> Dec 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    bizalimogene ralaplasmid (VGX-3100)